✍️ By Kim Sun-kyung, HIT News
| Expanding global partnerships through an AI-powered digital clinical platform
| End-to-end support from clinical operations to regulatory strategy and licensing-out
Digital Transformation Reshapes Clinical Trials
As AI and cloud technologies spread across drug development, clinical trials are also going digital. Beyond data collection and management, new service models now support business strategy, global trials, regulatory approval, and licensing-out on a single platform.
At BIO International Convention 2026 in San Diego, JNPMEDI showcased its digital clinical platform and clinical development consulting capabilities to global partners. HIT News spoke in writing with Sungkyoung Lee, Head of JNPMEDI’s S&BD Center, about the event and the company’s future strategy.
What did JNPMEDI focus on at the event?
“JNPMEDI began as a clinical data software company and has since expanded into a clinical development consulting company supporting the research, development, and commercialization (RDC) of global pharmaceutical and medical device companies.
At this event, we focused on two areas to strengthen our position as an AI platform-based consulting company for drug and innovative medical device development: our digital clinical capabilities for companies preparing to enter global markets, and our ‘business boosting’ model, which supports and manages licensing-out activities for Korean biotech companies.
JNPMEDI’s key strength in driving digital transformation across the CRO industry lies in its end-to-end, on-demand solutions as a Life Science RDC company.
This model supports the full development lifecycle, from product planning and business strategy to development, multinational clinical trials, global regulatory affairs, and licensing-out.
All RDC services are built on Maven Clinical Cloud, our flagship platform. Powered by AI and a modern data architecture, it supports clinical operations and data management.
The platform ensures clinical data integrity while offering an intuitive UI/UX and the flexibility to adopt only the functions needed. It also helps improve patient engagement and optimize operational resources in multinational clinical trials. Based on these capabilities, it supports compliance with strict global regulatory data standards, including CDISC requirements for FDA IND and medical device IDE submissions.
We also highlighted the synergy between our digital platform and Professional Services team, which includes physicians, pharmacists, and regulatory experts. Our message to global partners was clear: JNPMEDI is not simply a software provider, but an end-to-end partner supporting global business success.”
How many global companies did JNPMEDI meet with, and how did they respond?
“We met with around 20 global big pharma and mid-sized pharmaceutical companies whose interests aligned with the pipelines of the biotech companies we advise.
We tailored each pitch to the progress and strengths of the relevant pipeline. Several confidentiality agreements (CDAs) have also been proposed or are in progress to explore potential licensing-out opportunities.
Partners also showed strong interest in Maven Clinical Cloud, particularly its ability to support hybrid trials combining traditional and decentralized models.
At the Korea Special Biotech Showcase, we introduced our full-scope Life Science RDC model, covering investment, clinical development, commercialization, and licensing-out. This also led to further collaboration inquiries.”
What were the key outcomes?
“JNPMEDI served as a bridge between Korean biotech companies and global pharmaceutical partners, supporting licensing-out discussions.
Many Korean biotech startups have strong science but limited in-house resources for global business development and clinical strategy. We help close this gap through our global network and expertise.
As a result, we signed CDAs with global pharmaceutical companies during the event and are continuing discussions on clinical and business partnerships.”
What are JNPMEDI’s main plans through the first half of next year?
“Building on the network and CDAs established at BIO USA 2026, we will focus on licensing-out deals and due diligence for the biotech companies we advise.
We also plan to expand multinational clinical trial contracts through Maven Clinical Cloud. Our Singapore office will strengthen APAC partnerships, while our US office will support broader global expansion.
In addition, we will continue to advance FDA IND and medical device IDE projects through our network of more than 200 global KOLs, overseas CRO partnerships, and full-scope RDC capabilities.”
What would you like to share with the industry and investors?
“JNPMEDI began as a clinical data software company and has grown into a full-scope RDC partner for pharmaceutical and medical device companies targeting global markets.
By combining digital technology with clinical development expertise, we aim to lower the barriers Korean biotech companies face in global clinical development and commercialization.
We will continue to become a trusted partner for Korean companies entering global markets and help Korean biotechnology achieve meaningful results worldwide.”
✍️ By Kim Sun-kyung, HIT News
| Expanding global partnerships through an AI-powered digital clinical platform
| End-to-end support from clinical operations to regulatory strategy and licensing-out
Digital Transformation Reshapes Clinical Trials
As AI and cloud technologies spread across drug development, clinical trials are also going digital. Beyond data collection and management, new service models now support business strategy, global trials, regulatory approval, and licensing-out on a single platform.
At BIO International Convention 2026 in San Diego, JNPMEDI showcased its digital clinical platform and clinical development consulting capabilities to global partners. HIT News spoke in writing with Sungkyoung Lee, Head of JNPMEDI’s S&BD Center, about the event and the company’s future strategy.
What did JNPMEDI focus on at the event?
“JNPMEDI began as a clinical data software company and has since expanded into a clinical development consulting company supporting the research, development, and commercialization (RDC) of global pharmaceutical and medical device companies.
At this event, we focused on two areas to strengthen our position as an AI platform-based consulting company for drug and innovative medical device development: our digital clinical capabilities for companies preparing to enter global markets, and our ‘business boosting’ model, which supports and manages licensing-out activities for Korean biotech companies.
JNPMEDI’s key strength in driving digital transformation across the CRO industry lies in its end-to-end, on-demand solutions as a Life Science RDC company.
This model supports the full development lifecycle, from product planning and business strategy to development, multinational clinical trials, global regulatory affairs, and licensing-out.
All RDC services are built on Maven Clinical Cloud, our flagship platform. Powered by AI and a modern data architecture, it supports clinical operations and data management.
The platform ensures clinical data integrity while offering an intuitive UI/UX and the flexibility to adopt only the functions needed. It also helps improve patient engagement and optimize operational resources in multinational clinical trials. Based on these capabilities, it supports compliance with strict global regulatory data standards, including CDISC requirements for FDA IND and medical device IDE submissions.
We also highlighted the synergy between our digital platform and Professional Services team, which includes physicians, pharmacists, and regulatory experts. Our message to global partners was clear: JNPMEDI is not simply a software provider, but an end-to-end partner supporting global business success.”
How many global companies did JNPMEDI meet with, and how did they respond?
“We met with around 20 global big pharma and mid-sized pharmaceutical companies whose interests aligned with the pipelines of the biotech companies we advise.
We tailored each pitch to the progress and strengths of the relevant pipeline. Several confidentiality agreements (CDAs) have also been proposed or are in progress to explore potential licensing-out opportunities.
Partners also showed strong interest in Maven Clinical Cloud, particularly its ability to support hybrid trials combining traditional and decentralized models.
At the Korea Special Biotech Showcase, we introduced our full-scope Life Science RDC model, covering investment, clinical development, commercialization, and licensing-out. This also led to further collaboration inquiries.”
What were the key outcomes?
“JNPMEDI served as a bridge between Korean biotech companies and global pharmaceutical partners, supporting licensing-out discussions.
Many Korean biotech startups have strong science but limited in-house resources for global business development and clinical strategy. We help close this gap through our global network and expertise.
As a result, we signed CDAs with global pharmaceutical companies during the event and are continuing discussions on clinical and business partnerships.”
What are JNPMEDI’s main plans through the first half of next year?
“Building on the network and CDAs established at BIO USA 2026, we will focus on licensing-out deals and due diligence for the biotech companies we advise.
We also plan to expand multinational clinical trial contracts through Maven Clinical Cloud. Our Singapore office will strengthen APAC partnerships, while our US office will support broader global expansion.
In addition, we will continue to advance FDA IND and medical device IDE projects through our network of more than 200 global KOLs, overseas CRO partnerships, and full-scope RDC capabilities.”
What would you like to share with the industry and investors?
“JNPMEDI began as a clinical data software company and has grown into a full-scope RDC partner for pharmaceutical and medical device companies targeting global markets.
By combining digital technology with clinical development expertise, we aim to lower the barriers Korean biotech companies face in global clinical development and commercialization.
We will continue to become a trusted partner for Korean companies entering global markets and help Korean biotechnology achieve meaningful results worldwide.”